All In Biotech

Drug Trial Radar · NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Dec 22, 2025

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ICP-332 TabletsDrug

    ICP-332 will be administered as tablet for 12 weeks

  • ICP-332 TabletsDrug

    ICP-332 will be administered as tablet for 12 weeks

  • ICP-332 TabletsDrug

    ICP-332 will be administered as tablet for 12 weeks

  • ICP-332 Placebo TabletsOther

    Placebo will be administered as tablet for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12Time frame: Day 1 to Day 85

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Tongren Hospital, Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • Chongqing Traditional Chinese Medicine Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University First Affiliated Hospital

    Fuzhou, Fujian, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shandong Provincial Hospital of Dermatology

    Jinan, Shandong, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Dermatology Hospital

    Shanghai, Shanghai Municipality, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.